Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.

Source:http://linkedlifedata.com/resource/pubmed/id/20231530

Circulation 2010 Mar 30 121 12 1413-22

Download in:

View as

General Info

PMID
20231530